Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content
Cancer PHGKB

Specific PHGKB|Cancer|Public Health Genomics and Precision Health Knowledge Base (PHGKB)
Effective August 1, 2024, this database was discontinued. All content will remain searchable and be preserved online for historical purposes only until 2029.

spot light Spotlight

The Path to Genomic Screening—Far From Simple, but the Journey Has Begun

From the article: "Today’s genomic technology introduces a multitude of assays that could be deployed in health care: diagnostic testing of patients with suspected monogenic conditions, polygenic risk prediction for common diseases, pharmacogenomic analysis for drug-gene interactions, analysis of tumors for targetable somatic sequence variations, and noninvasive screening for prenatal chromosomal disorders or occult cancer. Alongside these approaches we must also grapple with screening of the ostensibly healthy population for monogenic diseases of newborns, children, and adults with either targeted or genome-scale sequencing. "

Screening Familial Risk for Hereditary Breast and Ovarian Cancer

From the abstract: "In a large health system, how many ungenotyped patients meet family history genetic testing criteria for hereditary breast and ovarian cancer? In this cross-sectional analysis, 2.9% of patients had no evidence of prior genetic testing but had electronic health records indicating they met family history criteria. These criteria were associated with significantly increased prevalence of genetic risk variants among 38?003 genotyped patients. These findings suggest that substantial gaps exist in identifying and testing patients meeting family history criteria for hereditary breast and ovarian cancer, and other methods may be needed to close these gaps. "

Harnessing cancer genomes for precision oncology

From the abstract: "Precision oncology has just received a boost: a report on the prevalence of mutations in cancer driver genes based on whole genome sequencing of 10,000 clinical cases. The challenge ahead lies in how to explore the data to accelerate new discoveries in cancer biology while advancing precision oncology. "

Advancing Genomic Cancer Medicine in Rural and Underserved States

From the article: "In the evolving landscape of oncology, the integration of powerful genomic technologies into practice has ushered in a new era of precision cancer medicine. Complex genomic information such as mutational analyses, transcriptional signatures, and polygenic risk scores have become key diagnostics guiding therapeutic decisions and management of inherited cancer risk. However, the expertise to interpret these data for clinical decision-making remains constrained and is a significant challenge for community oncologists, especially those in rural regions and in medically underserved areas. While physical access to these tests is readily available, poor access to interpretive expertise has become the key limiting factor. "


news Latest News and Publications
Exosomes derived from syncytia induced by SARS-2-S promote the proliferation and metastasis of hepatocellular carcinoma cells. External Web Site Icon
Li Huilong, et al. Frontiers in cellular and infection microbiology 2025 0 0. 1415356
A Universal Therapeutic Vaccine Leveraging Autologous Pre-Existing Immunity to Eliminate in Situ Uniformly Engineered Heterogeneous Tumor Cells. External Web Site Icon
Wu Fuhua, et al. Advanced materials (Deerfield Beach, Fla.) 2025 0 0. e2412430
Deep learning models for CT image classification: a comprehensive literature review. External Web Site Icon
Ahmad Isah Salim, et al. Quantitative imaging in medicine and surgery 2025 0 0. (1) 962-1011
Predicting candidate biomarkers for COVID-19 associated with leukemia in children. External Web Site Icon
Bai Judy, et al. American journal of clinical and experimental immunology 2025 0 0. (6) 246-258
Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals. External Web Site Icon
Miyaji Karina Takesaki, et al. Revista do Instituto de Medicina Tropical de Sao Paulo 2025 0 0. e2
Current trends in pain management: A bibliometric analysis for the 1980-to-2023 period. External Web Site Icon
Demir Emre, et al. Medicine 2025 0 0. (3) e41319
Optimizing mRNA translation efficiency through rational 5'UTR and 3'UTR combinatorial design. External Web Site Icon
Li Ting, et al. Gene 2025 0 0. 149254
Advancing COVID-19 Treatment: The Role of Non-covalent Inhibitors Unveiled by Integrated Machine Learning and Network Pharmacology. External Web Site Icon
Qadir Saba, et al. Current pharmaceutical design 2025 0 0.
Better Outcomes for Ovarian Cancer Associated With the Detection of Anti-EBV TCR CDR3s: Potential Relevance to Diffuse Large B-Cell Lymphoma. External Web Site Icon
Goel Nandini, et al. American journal of reproductive immunology (New York, N.Y. : 1989) 2025 0 0. (1) e70046
Linking The Cancer Imaging Archive and GenBank to the National Clinical Cohort Collaborative. External Web Site Icon
Baghal Ahmad, et al. Learning health systems 2025 0 0. (1) e10457

More


Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.

TOP